New hope for advanced endometrial cancer: Triple-Drug combo trial launches
NCT ID NCT05077215
First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 25 times
Summary
This phase 3 trial tests whether adding the experimental drug EG007 to standard therapy (lenvatinib plus pembrolizumab) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 adults whose cancer has returned after platinum chemotherapy will be randomly assigned to receive either the triple combination or the standard two-drug therapy. The study will compare progression-free survival, overall survival, and tumor response between the groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.